 Debashis Ghosh
Concepts (833)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Gene Expression Profiling | 56 | 2025 | 1772 | 5.080 |
Why?
| | Data Interpretation, Statistical | 28 | 2020 | 363 | 4.600 |
Why?
| | Models, Statistical | 44 | 2024 | 667 | 4.560 |
Why?
| | Leishmaniasis, Visceral | 16 | 2024 | 22 | 4.450 |
Why?
| | Algorithms | 41 | 2025 | 1689 | 4.240 |
Why?
| | Oligonucleotide Array Sequence Analysis | 38 | 2016 | 766 | 3.400 |
Why?
| | Machine Learning | 10 | 2024 | 487 | 2.710 |
Why?
| | Computer Simulation | 36 | 2024 | 973 | 2.690 |
Why?
| | Computational Biology | 20 | 2025 | 643 | 2.640 |
Why?
| | Psychodidae | 7 | 2023 | 8 | 2.260 |
Why?
| | Biomarkers, Tumor | 25 | 2022 | 1272 | 2.230 |
Why?
| | Metabolomics | 9 | 2022 | 678 | 2.200 |
Why?
| | Biometry | 13 | 2011 | 70 | 2.140 |
Why?
| | Prostatic Neoplasms | 28 | 2024 | 1034 | 1.860 |
Why?
| | Retinol-Binding Proteins | 5 | 2016 | 18 | 1.780 |
Why?
| | Neoplasms | 25 | 2024 | 2644 | 1.730 |
Why?
| | Eye Proteins | 6 | 2016 | 92 | 1.720 |
Why?
| | Software | 15 | 2025 | 665 | 1.710 |
Why?
| | Phlebotomus | 5 | 2023 | 5 | 1.470 |
Why?
| | Regression Analysis | 13 | 2021 | 1022 | 1.470 |
Why?
| | Leishmaniasis, Cutaneous | 4 | 2024 | 14 | 1.460 |
Why?
| | Genomics | 12 | 2024 | 790 | 1.360 |
Why?
| | Neoplasm Proteins | 12 | 2018 | 434 | 1.320 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 4 | 2023 | 1036 | 1.320 |
Why?
| | Models, Biological | 14 | 2021 | 1773 | 1.300 |
Why?
| | Gene Expression Regulation, Neoplastic | 24 | 2021 | 1396 | 1.280 |
Why?
| | Humans | 196 | 2025 | 136768 | 1.230 |
Why?
| | Statistics, Nonparametric | 8 | 2019 | 431 | 1.150 |
Why?
| | Causality | 4 | 2022 | 126 | 1.150 |
Why?
| | Databases, Factual | 12 | 2024 | 1351 | 1.140 |
Why?
| | Biomarkers | 14 | 2021 | 4144 | 1.140 |
Why?
| | Proportional Hazards Models | 10 | 2022 | 1261 | 1.120 |
Why?
| | Insecticides | 4 | 2023 | 38 | 1.090 |
Why?
| | Insect Control | 4 | 2023 | 16 | 1.080 |
Why?
| | Biostatistics | 3 | 2014 | 18 | 1.070 |
Why?
| | Insect Vectors | 4 | 2023 | 39 | 1.060 |
Why?
| | Aromatase | 2 | 2019 | 32 | 1.020 |
Why?
| | Bangladesh | 13 | 2024 | 56 | 1.010 |
Why?
| | Survival Analysis | 12 | 2024 | 1321 | 1.010 |
Why?
| | Endemic Diseases | 2 | 2024 | 32 | 1.000 |
Why?
| | Natural Gas | 1 | 2025 | 24 | 0.930 |
Why?
| | Oil and Gas Fields | 1 | 2025 | 31 | 0.920 |
Why?
| | Meta-Analysis as Topic | 4 | 2014 | 186 | 0.920 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2025 | 288 | 0.900 |
Why?
| | Microscopy | 3 | 2023 | 145 | 0.880 |
Why?
| | Magnetoencephalography | 2 | 2021 | 149 | 0.870 |
Why?
| | Leishmania donovani | 5 | 2022 | 12 | 0.860 |
Why?
| | Colonic Neoplasms | 2 | 2022 | 254 | 0.850 |
Why?
| | Histological Techniques | 1 | 2023 | 40 | 0.830 |
Why?
| | Environmental Exposure | 3 | 2025 | 572 | 0.810 |
Why?
| | Genetic Association Studies | 5 | 2019 | 375 | 0.800 |
Why?
| | Lung Neoplasms | 6 | 2022 | 2489 | 0.800 |
Why?
| | Multivariate Analysis | 16 | 2022 | 1507 | 0.790 |
Why?
| | Models, Genetic | 11 | 2019 | 599 | 0.790 |
Why?
| | Zebrafish Proteins | 2 | 2016 | 286 | 0.790 |
Why?
| | Sequence Analysis, RNA | 1 | 2025 | 452 | 0.780 |
Why?
| | Single-Cell Analysis | 1 | 2025 | 311 | 0.770 |
Why?
| | Cognitive Dysfunction | 4 | 2021 | 381 | 0.760 |
Why?
| | Pyrethrins | 1 | 2021 | 8 | 0.750 |
Why?
| | Connectome | 2 | 2021 | 85 | 0.740 |
Why?
| | Parkinsonian Disorders | 1 | 2021 | 35 | 0.720 |
Why?
| | Mass Spectrometry | 6 | 2022 | 738 | 0.720 |
Why?
| | Brain | 4 | 2024 | 2664 | 0.720 |
Why?
| | Brain Mapping | 2 | 2021 | 504 | 0.710 |
Why?
| | Housing | 2 | 2021 | 146 | 0.690 |
Why?
| | Nitriles | 1 | 2021 | 172 | 0.690 |
Why?
| | Endpoint Determination | 2 | 2011 | 77 | 0.680 |
Why?
| | Propensity Score | 4 | 2018 | 289 | 0.680 |
Why?
| | Cluster Analysis | 12 | 2024 | 497 | 0.670 |
Why?
| | Feasibility Studies | 2 | 2024 | 951 | 0.670 |
Why?
| | Phenotype | 12 | 2023 | 3189 | 0.650 |
Why?
| | Clinical Trials as Topic | 4 | 2022 | 1044 | 0.650 |
Why?
| | Image Processing, Computer-Assisted | 7 | 2024 | 752 | 0.640 |
Why?
| | Placenta | 2 | 2019 | 749 | 0.630 |
Why?
| | High-Throughput Screening Assays | 2 | 2012 | 158 | 0.630 |
Why?
| | Risk Assessment | 8 | 2020 | 3432 | 0.630 |
Why?
| | Learning | 1 | 2023 | 406 | 0.630 |
Why?
| | Diagnostic Imaging | 1 | 2022 | 328 | 0.630 |
Why?
| | Radiographic Image Interpretation, Computer-Assisted | 1 | 2020 | 107 | 0.630 |
Why?
| | Databases, Genetic | 11 | 2021 | 237 | 0.620 |
Why?
| | Genetic Variation | 4 | 2019 | 985 | 0.610 |
Why?
| | Quantitative Trait, Heritable | 2 | 2018 | 125 | 0.610 |
Why?
| | DNA Copy Number Variations | 2 | 2017 | 182 | 0.600 |
Why?
| | Metabolome | 1 | 2021 | 350 | 0.580 |
Why?
| | Transcriptome | 2 | 2023 | 969 | 0.560 |
Why?
| | Glioma | 1 | 2022 | 395 | 0.560 |
Why?
| | Logistic Models | 12 | 2020 | 2067 | 0.560 |
Why?
| | Protein Conformation | 4 | 2015 | 933 | 0.560 |
Why?
| | Randomized Controlled Trials as Topic | 5 | 2021 | 1462 | 0.550 |
Why?
| | Reproducibility of Results | 17 | 2021 | 3264 | 0.550 |
Why?
| | Cardiovascular Diseases | 5 | 2022 | 2104 | 0.550 |
Why?
| | Epidemiologic Methods | 2 | 2007 | 96 | 0.530 |
Why?
| | Male | 73 | 2025 | 67311 | 0.530 |
Why?
| | Immunohistochemistry | 11 | 2022 | 1733 | 0.520 |
Why?
| | Registries | 2 | 2024 | 2015 | 0.510 |
Why?
| | Markov Chains | 7 | 2017 | 123 | 0.490 |
Why?
| | Sensitivity and Specificity | 12 | 2024 | 1935 | 0.480 |
Why?
| | Cytochrome P-450 Enzyme System | 2 | 2016 | 155 | 0.480 |
Why?
| | Linear Models | 7 | 2018 | 846 | 0.480 |
Why?
| | Crystallography, X-Ray | 7 | 2019 | 476 | 0.460 |
Why?
| | Empirical Research | 2 | 2012 | 21 | 0.460 |
Why?
| | Female | 59 | 2025 | 72796 | 0.450 |
Why?
| | Bayes Theorem | 7 | 2022 | 404 | 0.450 |
Why?
| | Case-Control Studies | 10 | 2025 | 3540 | 0.450 |
Why?
| | Protein Folding | 1 | 2016 | 280 | 0.450 |
Why?
| | Diagnosis, Computer-Assisted | 4 | 2008 | 89 | 0.440 |
Why?
| | Autism Spectrum Disorder | 2 | 2017 | 395 | 0.440 |
Why?
| | Lupus Nephritis | 2 | 2025 | 63 | 0.440 |
Why?
| | Nerve Net | 3 | 2024 | 256 | 0.430 |
Why?
| | Carcinoma, Squamous Cell | 4 | 2017 | 683 | 0.430 |
Why?
| | Statistics as Topic | 3 | 2025 | 307 | 0.420 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 2022 | 1076 | 0.420 |
Why?
| | Neuroendocrine Tumors | 3 | 2024 | 116 | 0.410 |
Why?
| | Genome-Wide Association Study | 7 | 2018 | 1428 | 0.410 |
Why?
| | Protein Tyrosine Phosphatases | 3 | 2019 | 172 | 0.400 |
Why?
| | Spectrometry, Fluorescence | 4 | 2016 | 168 | 0.400 |
Why?
| | India | 6 | 2023 | 193 | 0.400 |
Why?
| | Bias | 5 | 2022 | 218 | 0.400 |
Why?
| | Treatment Outcome | 9 | 2023 | 10744 | 0.390 |
Why?
| | Disease Progression | 15 | 2021 | 2750 | 0.390 |
Why?
| | Tissue Array Analysis | 3 | 2008 | 57 | 0.390 |
Why?
| | Oncogenes | 1 | 2013 | 116 | 0.380 |
Why?
| | Sulfhydryl Compounds | 1 | 2014 | 189 | 0.370 |
Why?
| | Animals | 33 | 2025 | 36847 | 0.370 |
Why?
| | Genome | 5 | 2017 | 294 | 0.360 |
Why?
| | Cardiac Catheterization | 1 | 2015 | 527 | 0.360 |
Why?
| | Insecticide-Treated Bednets | 3 | 2021 | 6 | 0.360 |
Why?
| | Nerve Tissue Proteins | 4 | 2023 | 595 | 0.350 |
Why?
| | Diabetes Mellitus, Type 2 | 3 | 2022 | 2518 | 0.350 |
Why?
| | Alzheimer Disease | 3 | 2015 | 558 | 0.340 |
Why?
| | Supervised Machine Learning | 2 | 2021 | 17 | 0.340 |
Why?
| | Precision Medicine | 2 | 2025 | 426 | 0.340 |
Why?
| | Child, Preschool | 9 | 2025 | 11000 | 0.330 |
Why?
| | Adenocarcinoma | 4 | 2017 | 938 | 0.330 |
Why?
| | Polymorphism, Single Nucleotide | 5 | 2019 | 2184 | 0.330 |
Why?
| | Models, Neurological | 2 | 2024 | 242 | 0.330 |
Why?
| | Antioxidants | 1 | 2014 | 584 | 0.330 |
Why?
| | Gene Expression | 3 | 2014 | 1500 | 0.320 |
Why?
| | Colorado | 6 | 2025 | 4518 | 0.320 |
Why?
| | Endoplasmic Reticulum | 1 | 2012 | 264 | 0.320 |
Why?
| | Stem Cells | 3 | 2020 | 592 | 0.320 |
Why?
| | Ki-67 Antigen | 2 | 2020 | 111 | 0.310 |
Why?
| | Signal Transduction | 10 | 2025 | 5076 | 0.310 |
Why?
| | Epidemiologic Research Design | 1 | 2009 | 29 | 0.310 |
Why?
| | Gene Dosage | 1 | 2010 | 140 | 0.310 |
Why?
| | Aged | 29 | 2024 | 23794 | 0.310 |
Why?
| | Risk Factors | 14 | 2025 | 10326 | 0.300 |
Why?
| | Chromatin Immunoprecipitation | 3 | 2017 | 138 | 0.300 |
Why?
| | Middle Aged | 34 | 2024 | 33228 | 0.300 |
Why?
| | Child | 16 | 2025 | 21822 | 0.300 |
Why?
| | Liver Neoplasms | 1 | 2015 | 785 | 0.300 |
Why?
| | Protein Array Analysis | 8 | 2009 | 57 | 0.290 |
Why?
| | Bone Marrow Transplantation | 2 | 2008 | 287 | 0.290 |
Why?
| | Proteomics | 5 | 2009 | 1109 | 0.290 |
Why?
| | Emigration and Immigration | 1 | 2008 | 46 | 0.290 |
Why?
| | Racemases and Epimerases | 5 | 2006 | 11 | 0.290 |
Why?
| | Carcinoma | 2 | 2007 | 238 | 0.290 |
Why?
| | Statistical Distributions | 1 | 2008 | 8 | 0.290 |
Why?
| | Tumor Microenvironment | 2 | 2022 | 672 | 0.290 |
Why?
| | Probability | 3 | 2021 | 304 | 0.280 |
Why?
| | Chromosome Mapping | 6 | 2017 | 523 | 0.280 |
Why?
| | Arrhythmias, Cardiac | 2 | 2020 | 333 | 0.270 |
Why?
| | DNA-Binding Proteins | 7 | 2018 | 1501 | 0.270 |
Why?
| | DNA Methylation | 4 | 2023 | 640 | 0.270 |
Why?
| | Research Design | 5 | 2021 | 1127 | 0.270 |
Why?
| | Flow Cytometry | 2 | 2022 | 1180 | 0.270 |
Why?
| | Tumor Burden | 1 | 2008 | 309 | 0.260 |
Why?
| | Adult | 27 | 2024 | 37630 | 0.260 |
Why?
| | Proteome | 3 | 2007 | 472 | 0.260 |
Why?
| | Pancreas | 2 | 2020 | 329 | 0.250 |
Why?
| | Urinary Bladder Neoplasms | 2 | 2021 | 251 | 0.250 |
Why?
| | Monte Carlo Method | 4 | 2017 | 147 | 0.240 |
Why?
| | Diabetes Mellitus | 5 | 2022 | 1032 | 0.240 |
Why?
| | Triple Negative Breast Neoplasms | 2 | 2019 | 202 | 0.240 |
Why?
| | Interleukin-2 Receptor beta Subunit | 1 | 2025 | 27 | 0.240 |
Why?
| | Neoplasm Staging | 6 | 2019 | 1371 | 0.230 |
Why?
| | Cell Proliferation | 5 | 2021 | 2475 | 0.230 |
Why?
| | False Positive Reactions | 4 | 2012 | 115 | 0.230 |
Why?
| | Class I Phosphatidylinositol 3-Kinases | 1 | 2025 | 95 | 0.230 |
Why?
| | Homeodomain Proteins | 4 | 2020 | 506 | 0.230 |
Why?
| | High-Throughput Nucleotide Sequencing | 3 | 2025 | 535 | 0.230 |
Why?
| | Cell Nucleus | 2 | 2019 | 617 | 0.230 |
Why?
| | Amino Acid Sequence | 3 | 2016 | 2138 | 0.230 |
Why?
| | Replication Origin | 1 | 2004 | 19 | 0.230 |
Why?
| | Magnetic Resonance Imaging | 5 | 2022 | 3555 | 0.220 |
Why?
| | Fever | 2 | 2023 | 306 | 0.220 |
Why?
| | Genetic Predisposition to Disease | 5 | 2023 | 2412 | 0.220 |
Why?
| | Viral Nonstructural Proteins | 1 | 2024 | 65 | 0.220 |
Why?
| | Dengue Virus | 1 | 2024 | 52 | 0.220 |
Why?
| | Weather | 1 | 2024 | 40 | 0.220 |
Why?
| | Data Curation | 1 | 2024 | 16 | 0.220 |
Why?
| | Adolescent | 12 | 2025 | 21382 | 0.220 |
Why?
| | Leukemia | 1 | 2006 | 238 | 0.210 |
Why?
| | ROC Curve | 5 | 2020 | 545 | 0.210 |
Why?
| | Antigens | 1 | 2005 | 358 | 0.210 |
Why?
| | Dengue | 1 | 2024 | 80 | 0.210 |
Why?
| | Carrier Proteins | 2 | 2007 | 769 | 0.210 |
Why?
| | Ligands | 2 | 2016 | 661 | 0.210 |
Why?
| | Neoplasm Recurrence, Local | 3 | 2019 | 1058 | 0.210 |
Why?
| | Melanoma | 3 | 2005 | 757 | 0.210 |
Why?
| | Cell Phone | 1 | 2024 | 75 | 0.210 |
Why?
| | Sample Size | 3 | 2008 | 125 | 0.210 |
Why?
| | Histones | 4 | 2020 | 636 | 0.210 |
Why?
| | Coculture Techniques | 1 | 2004 | 239 | 0.200 |
Why?
| | Staining and Labeling | 1 | 2023 | 148 | 0.200 |
Why?
| | Recurrence | 5 | 2023 | 1055 | 0.200 |
Why?
| | Common Variable Immunodeficiency | 1 | 2023 | 29 | 0.200 |
Why?
| | Skin Diseases, Parasitic | 1 | 2022 | 3 | 0.200 |
Why?
| | Membrane Transport Proteins | 1 | 2004 | 162 | 0.200 |
Why?
| | Carcinogens | 1 | 2003 | 124 | 0.200 |
Why?
| | Organometallic Compounds | 1 | 2023 | 111 | 0.200 |
Why?
| | Neoplasms, Experimental | 1 | 2003 | 176 | 0.200 |
Why?
| | Social Stigma | 1 | 2024 | 134 | 0.200 |
Why?
| | Retina | 2 | 2016 | 298 | 0.200 |
Why?
| | Personality | 1 | 2004 | 132 | 0.200 |
Why?
| | Emphysema | 1 | 2023 | 106 | 0.190 |
Why?
| | DNA, Complementary | 4 | 2007 | 271 | 0.190 |
Why?
| | Biomedical Research | 2 | 2025 | 688 | 0.190 |
Why?
| | Neuroimaging | 2 | 2015 | 259 | 0.190 |
Why?
| | Breast Neoplasms | 7 | 2014 | 2234 | 0.190 |
Why?
| | Parasites | 1 | 2022 | 50 | 0.190 |
Why?
| | Estrogens | 2 | 2019 | 367 | 0.190 |
Why?
| | Lymphoma, Large B-Cell, Diffuse | 2 | 2019 | 122 | 0.190 |
Why?
| | Construction Materials | 1 | 2021 | 15 | 0.180 |
Why?
| | Infant | 3 | 2024 | 9398 | 0.180 |
Why?
| | Promoter Regions, Genetic | 3 | 2009 | 1249 | 0.180 |
Why?
| | Tomography, X-Ray Computed | 2 | 2023 | 2667 | 0.180 |
Why?
| | Leishmania | 1 | 2021 | 3 | 0.180 |
Why?
| | Brain Waves | 1 | 2021 | 34 | 0.180 |
Why?
| | Young Adult | 11 | 2024 | 13129 | 0.180 |
Why?
| | Membrane Glycoproteins | 1 | 2004 | 500 | 0.180 |
Why?
| | Zebrafish | 2 | 2016 | 495 | 0.180 |
Why?
| | Analysis of Variance | 4 | 2024 | 1316 | 0.180 |
Why?
| | Epilepsies, Partial | 1 | 2021 | 50 | 0.180 |
Why?
| | Epilepsy | 2 | 2021 | 331 | 0.180 |
Why?
| | Mutation, Missense | 2 | 2016 | 337 | 0.180 |
Why?
| | Lupus Erythematosus, Systemic | 1 | 2023 | 242 | 0.180 |
Why?
| | Receptors, Androgen | 2 | 2021 | 150 | 0.180 |
Why?
| | Polymorphism, Genetic | 1 | 2004 | 659 | 0.170 |
Why?
| | Autoantibodies | 5 | 2020 | 1496 | 0.170 |
Why?
| | Head and Neck Neoplasms | 2 | 2017 | 604 | 0.170 |
Why?
| | Genotype | 8 | 2019 | 1914 | 0.170 |
Why?
| | Anxiety Disorders | 1 | 2004 | 374 | 0.170 |
Why?
| | Hyaluronan Receptors | 1 | 2021 | 103 | 0.170 |
Why?
| | Amino Acid Motifs | 2 | 2019 | 225 | 0.170 |
Why?
| | Pulmonary Emphysema | 1 | 2023 | 288 | 0.170 |
Why?
| | Peptides | 4 | 2007 | 980 | 0.170 |
Why?
| | Pattern Recognition, Automated | 4 | 2009 | 73 | 0.170 |
Why?
| | Lymphocytes | 2 | 2023 | 393 | 0.170 |
Why?
| | RNA, Messenger | 8 | 2024 | 2831 | 0.170 |
Why?
| | Drug Resistant Epilepsy | 1 | 2021 | 102 | 0.160 |
Why?
| | Radiography | 1 | 2022 | 822 | 0.160 |
Why?
| | Herpes Zoster Vaccine | 1 | 2022 | 159 | 0.160 |
Why?
| | Toll-Like Receptors | 1 | 2020 | 185 | 0.160 |
Why?
| | Mexican Americans | 3 | 2008 | 120 | 0.160 |
Why?
| | Exome | 2 | 2018 | 230 | 0.160 |
Why?
| | Artificial Intelligence | 3 | 2008 | 275 | 0.160 |
Why?
| | Androgens | 3 | 2012 | 187 | 0.160 |
Why?
| | Patient Acceptance of Health Care | 2 | 2024 | 805 | 0.160 |
Why?
| | Hospital Mortality | 1 | 2024 | 901 | 0.160 |
Why?
| | Phosphorylation | 3 | 2019 | 1758 | 0.160 |
Why?
| | Disease Reservoirs | 1 | 2019 | 21 | 0.160 |
Why?
| | Protein Binding | 5 | 2019 | 2216 | 0.160 |
Why?
| | Tandem Mass Spectrometry | 3 | 2014 | 532 | 0.160 |
Why?
| | Tretinoin | 1 | 2020 | 123 | 0.160 |
Why?
| | Mice | 16 | 2025 | 17757 | 0.150 |
Why?
| | Prognosis | 11 | 2021 | 4013 | 0.150 |
Why?
| | Core Binding Factor Alpha 1 Subunit | 1 | 2019 | 40 | 0.150 |
Why?
| | Functional Neuroimaging | 1 | 2019 | 55 | 0.150 |
Why?
| | Bone Regeneration | 1 | 2019 | 25 | 0.150 |
Why?
| | Disease | 1 | 2019 | 98 | 0.150 |
Why?
| | Disease Transmission, Infectious | 1 | 2019 | 62 | 0.150 |
Why?
| | Pilot Projects | 2 | 2021 | 1692 | 0.150 |
Why?
| | Molecular Sequence Data | 4 | 2015 | 2894 | 0.150 |
Why?
| | Gene Expression Regulation | 4 | 2014 | 2605 | 0.150 |
Why?
| | Intensive Care Units | 1 | 2024 | 800 | 0.150 |
Why?
| | Small Molecule Libraries | 1 | 2019 | 94 | 0.150 |
Why?
| | Precancerous Conditions | 1 | 2020 | 169 | 0.150 |
Why?
| | Pituitary Gland | 2 | 2009 | 148 | 0.150 |
Why?
| | SOXB1 Transcription Factors | 1 | 2019 | 61 | 0.150 |
Why?
| | Multiple Sclerosis | 1 | 2024 | 455 | 0.150 |
Why?
| | Protein Structure, Tertiary | 3 | 2012 | 860 | 0.140 |
Why?
| | Genetic Markers | 3 | 2015 | 344 | 0.140 |
Why?
| | Nuclear Proteins | 2 | 2019 | 712 | 0.140 |
Why?
| | Herpes Zoster | 1 | 2022 | 316 | 0.140 |
Why?
| | Neoplasms, Second Primary | 1 | 2019 | 116 | 0.140 |
Why?
| | Wilms Tumor | 1 | 2019 | 86 | 0.140 |
Why?
| | Pancreatic Neoplasms | 3 | 2019 | 935 | 0.140 |
Why?
| | Observational Studies as Topic | 1 | 2018 | 116 | 0.140 |
Why?
| | Protein Phosphatase 2 | 1 | 2018 | 41 | 0.140 |
Why?
| | Monocytes | 1 | 2020 | 563 | 0.140 |
Why?
| | Pregnancy | 5 | 2019 | 6728 | 0.140 |
Why?
| | RNA, Neoplasm | 1 | 2017 | 82 | 0.140 |
Why?
| | CD24 Antigen | 1 | 2017 | 20 | 0.140 |
Why?
| | RNA, Small Interfering | 2 | 2019 | 622 | 0.140 |
Why?
| | Genes, Neoplasm | 3 | 2007 | 22 | 0.140 |
Why?
| | DNA, Neoplasm | 1 | 2017 | 164 | 0.130 |
Why?
| | Clinical Laboratory Techniques | 1 | 2018 | 97 | 0.130 |
Why?
| | Cross-Sectional Studies | 3 | 2024 | 5423 | 0.130 |
Why?
| | Osteogenesis | 1 | 2019 | 186 | 0.130 |
Why?
| | Epigenomics | 1 | 2017 | 115 | 0.130 |
Why?
| | Child Health | 1 | 2019 | 154 | 0.130 |
Why?
| | Clinical Trials, Phase III as Topic | 3 | 2012 | 105 | 0.130 |
Why?
| | Neoplasm Metastasis | 6 | 2019 | 657 | 0.130 |
Why?
| | Beryllium | 1 | 2018 | 153 | 0.130 |
Why?
| | Proto-Oncogene Proteins c-myc | 1 | 2018 | 139 | 0.130 |
Why?
| | Up-Regulation | 2 | 2018 | 844 | 0.130 |
Why?
| | Transcription, Genetic | 7 | 2013 | 1455 | 0.130 |
Why?
| | Induction Chemotherapy | 1 | 2017 | 74 | 0.130 |
Why?
| | Antley-Bixler Syndrome Phenotype | 1 | 2016 | 1 | 0.130 |
Why?
| | Principal Component Analysis | 1 | 2017 | 194 | 0.130 |
Why?
| | Calcium Compounds | 1 | 2016 | 5 | 0.130 |
Why?
| | Image Interpretation, Computer-Assisted | 1 | 2019 | 267 | 0.130 |
Why?
| | Tachycardia, Ventricular | 1 | 2018 | 175 | 0.130 |
Why?
| | Chemoradiotherapy, Adjuvant | 1 | 2016 | 43 | 0.130 |
Why?
| | RNA, Viral | 2 | 2024 | 654 | 0.130 |
Why?
| | Nurse Anesthetists | 1 | 2016 | 3 | 0.130 |
Why?
| | Anesthesia Department, Hospital | 1 | 2016 | 2 | 0.130 |
Why?
| | Memory, Short-Term | 1 | 2019 | 249 | 0.130 |
Why?
| | Normal Distribution | 2 | 2014 | 21 | 0.130 |
Why?
| | Chromosome Aberrations | 2 | 2007 | 155 | 0.130 |
Why?
| | Lung Diseases, Interstitial | 1 | 2023 | 636 | 0.130 |
Why?
| | Lymph Nodes | 1 | 2019 | 492 | 0.130 |
Why?
| | Anesthesia, Obstetrical | 1 | 2016 | 10 | 0.130 |
Why?
| | Mosquito Control | 1 | 2016 | 28 | 0.130 |
Why?
| | Salivary Gland Neoplasms | 1 | 2016 | 41 | 0.130 |
Why?
| | Tumor Cells, Cultured | 5 | 2021 | 953 | 0.130 |
Why?
| | Anus Neoplasms | 1 | 2016 | 33 | 0.130 |
Why?
| | Oxides | 1 | 2016 | 46 | 0.130 |
Why?
| | Transcription Factors | 6 | 2017 | 1718 | 0.130 |
Why?
| | ErbB Receptors | 2 | 2012 | 613 | 0.130 |
Why?
| | Analgesia, Obstetrical | 1 | 2016 | 20 | 0.130 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2019 | 455 | 0.130 |
Why?
| | Heart Arrest | 1 | 2020 | 338 | 0.130 |
Why?
| | Kaplan-Meier Estimate | 3 | 2017 | 888 | 0.130 |
Why?
| | Anesthesiologists | 1 | 2016 | 28 | 0.130 |
Why?
| | Health Services Research | 1 | 2019 | 399 | 0.120 |
Why?
| | Berylliosis | 1 | 2018 | 186 | 0.120 |
Why?
| | B7-H1 Antigen | 1 | 2018 | 217 | 0.120 |
Why?
| | Models, Theoretical | 1 | 2020 | 575 | 0.120 |
Why?
| | Transcriptional Activation | 1 | 2018 | 378 | 0.120 |
Why?
| | X-Ray Diffraction | 1 | 2016 | 104 | 0.120 |
Why?
| | Endopeptidases | 1 | 2016 | 90 | 0.120 |
Why?
| | Host-Pathogen Interactions | 1 | 2019 | 363 | 0.120 |
Why?
| | Parkinson Disease | 1 | 2021 | 490 | 0.120 |
Why?
| | Respiratory Sounds | 2 | 2007 | 125 | 0.120 |
Why?
| | Aged, 80 and over | 13 | 2022 | 7585 | 0.120 |
Why?
| | Anal Canal | 1 | 2016 | 97 | 0.120 |
Why?
| | Hypoglycemic Agents | 2 | 2021 | 1283 | 0.120 |
Why?
| | Cough | 2 | 2007 | 122 | 0.120 |
Why?
| | Insulin-Secreting Cells | 1 | 2020 | 372 | 0.120 |
Why?
| | Cell Transformation, Neoplastic | 4 | 2007 | 327 | 0.120 |
Why?
| | Oleic Acid | 1 | 2015 | 40 | 0.120 |
Why?
| | Proteolysis | 1 | 2016 | 177 | 0.120 |
Why?
| | Mutation | 2 | 2025 | 3946 | 0.120 |
Why?
| | Defibrillators, Implantable | 1 | 2018 | 315 | 0.120 |
Why?
| | HIV Infections | 3 | 2022 | 2828 | 0.120 |
Why?
| | Atrial Fibrillation | 1 | 2020 | 388 | 0.120 |
Why?
| | Air Pollution | 2 | 2017 | 315 | 0.110 |
Why?
| | Schizophrenia | 1 | 2019 | 438 | 0.110 |
Why?
| | Risk | 1 | 2017 | 908 | 0.110 |
Why?
| | Hypocreales | 1 | 2014 | 8 | 0.110 |
Why?
| | Colorectal Neoplasms | 3 | 2012 | 791 | 0.110 |
Why?
| | Cancer Survivors | 1 | 2019 | 280 | 0.110 |
Why?
| | Kidney Neoplasms | 1 | 2019 | 401 | 0.110 |
Why?
| | Blood Glucose | 2 | 2022 | 2181 | 0.110 |
Why?
| | Cell Differentiation | 2 | 2020 | 1982 | 0.110 |
Why?
| | Neoplastic Stem Cells | 1 | 2019 | 399 | 0.110 |
Why?
| | Gastrointestinal Microbiome | 1 | 2022 | 697 | 0.110 |
Why?
| | Time Factors | 5 | 2016 | 6808 | 0.110 |
Why?
| | Discriminant Analysis | 3 | 2020 | 37 | 0.110 |
Why?
| | Ants | 1 | 2014 | 25 | 0.110 |
Why?
| | Catalysis | 2 | 2012 | 307 | 0.110 |
Why?
| | Executive Function | 1 | 2019 | 440 | 0.110 |
Why?
| | Metmyoglobin | 1 | 2014 | 2 | 0.110 |
Why?
| | Sulfonic Acids | 1 | 2014 | 13 | 0.110 |
Why?
| | Influenza Vaccines | 1 | 2019 | 537 | 0.110 |
Why?
| | Treatment Failure | 1 | 2015 | 354 | 0.110 |
Why?
| | Chromatography, Ion Exchange | 1 | 2014 | 54 | 0.110 |
Why?
| | Survival Rate | 4 | 2019 | 1963 | 0.110 |
Why?
| | Benzothiazoles | 1 | 2014 | 33 | 0.110 |
Why?
| | Chromatography, Affinity | 1 | 2014 | 88 | 0.110 |
Why?
| | Longitudinal Studies | 4 | 2018 | 2829 | 0.110 |
Why?
| | Antiprotozoal Agents | 1 | 2013 | 16 | 0.110 |
Why?
| | Chromatography, Gel | 1 | 2014 | 127 | 0.110 |
Why?
| | Amphotericin B | 1 | 2013 | 31 | 0.110 |
Why?
| | Cell Line, Tumor | 7 | 2019 | 3405 | 0.110 |
Why?
| | Free Radical Scavengers | 1 | 2014 | 88 | 0.110 |
Why?
| | Acquired Immunodeficiency Syndrome | 1 | 2015 | 230 | 0.110 |
Why?
| | Brain Diseases | 1 | 2015 | 141 | 0.100 |
Why?
| | Crystallization | 1 | 2014 | 141 | 0.100 |
Why?
| | Odds Ratio | 3 | 2020 | 1065 | 0.100 |
Why?
| | Embryonic Stem Cells | 1 | 2014 | 123 | 0.100 |
Why?
| | Trans-Activators | 3 | 2020 | 398 | 0.100 |
Why?
| | Cohort Studies | 8 | 2017 | 5701 | 0.100 |
Why?
| | Influenza, Human | 1 | 2019 | 618 | 0.100 |
Why?
| | Follow-Up Studies | 5 | 2023 | 5106 | 0.100 |
Why?
| | Estradiol | 2 | 2014 | 518 | 0.100 |
Why?
| | Rhodium | 1 | 2012 | 2 | 0.100 |
Why?
| | Interleukin-2 | 2 | 2025 | 455 | 0.100 |
Why?
| | Positron-Emission Tomography | 2 | 2024 | 293 | 0.090 |
Why?
| | Molecular Diagnostic Techniques | 2 | 2024 | 105 | 0.090 |
Why?
| | Influenza A Virus, H5N1 Subtype | 1 | 2011 | 8 | 0.090 |
Why?
| | Electronic Health Records | 1 | 2020 | 1046 | 0.090 |
Why?
| | Mice, Inbred BALB C | 3 | 2019 | 1269 | 0.090 |
Why?
| | Least-Squares Analysis | 2 | 2020 | 79 | 0.090 |
Why?
| | Silver | 1 | 2012 | 38 | 0.090 |
Why?
| | CD8-Positive T-Lymphocytes | 3 | 2025 | 913 | 0.090 |
Why?
| | Androstadienes | 1 | 2012 | 107 | 0.090 |
Why?
| | Xenograft Model Antitumor Assays | 3 | 2021 | 868 | 0.090 |
Why?
| | Repressor Proteins | 2 | 2007 | 427 | 0.090 |
Why?
| | Gene Silencing | 3 | 2007 | 195 | 0.090 |
Why?
| | Transcription Factor Pit-1 | 1 | 2011 | 27 | 0.090 |
Why?
| | Otx Transcription Factors | 1 | 2011 | 13 | 0.090 |
Why?
| | Hypopituitarism | 1 | 2011 | 15 | 0.090 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 4 | 2024 | 975 | 0.090 |
Why?
| | Arthritis, Rheumatoid | 1 | 2020 | 1167 | 0.090 |
Why?
| | Motion | 1 | 2012 | 98 | 0.090 |
Why?
| | Heme | 1 | 2012 | 78 | 0.090 |
Why?
| | Brucella suis | 1 | 2011 | 1 | 0.090 |
Why?
| | Brucellosis | 1 | 2011 | 2 | 0.090 |
Why?
| | Regulatory Sequences, Nucleic Acid | 2 | 2017 | 91 | 0.090 |
Why?
| | Caspase 2 | 1 | 2011 | 13 | 0.090 |
Why?
| | Gene Expression Regulation, Viral | 1 | 2011 | 93 | 0.090 |
Why?
| | Prostatic Intraepithelial Neoplasia | 2 | 2008 | 11 | 0.090 |
Why?
| | Cattle | 1 | 2014 | 981 | 0.090 |
Why?
| | Lipid Bilayers | 1 | 2012 | 97 | 0.090 |
Why?
| | Catalytic Domain | 1 | 2012 | 207 | 0.090 |
Why?
| | Chemoradiotherapy | 3 | 2017 | 225 | 0.090 |
Why?
| | Real-Time Polymerase Chain Reaction | 2 | 2022 | 346 | 0.090 |
Why?
| | MicroRNAs | 1 | 2017 | 692 | 0.090 |
Why?
| | Lung | 2 | 2023 | 4062 | 0.090 |
Why?
| | Pharmacogenetics | 1 | 2012 | 179 | 0.090 |
Why?
| | Age Factors | 3 | 2020 | 3284 | 0.090 |
Why?
| | Neoplasm Invasiveness | 4 | 2017 | 507 | 0.090 |
Why?
| | Chemokines | 1 | 2011 | 228 | 0.090 |
Why?
| | Stress Disorders, Post-Traumatic | 2 | 2019 | 842 | 0.090 |
Why?
| | Pediatrics | 1 | 2019 | 1096 | 0.090 |
Why?
| | Vaccination | 1 | 2019 | 1377 | 0.090 |
Why?
| | Mental Disorders | 1 | 2019 | 1070 | 0.080 |
Why?
| | Influenza A Virus, H1N1 Subtype | 1 | 2011 | 149 | 0.080 |
Why?
| | Zalcitabine | 1 | 2010 | 2 | 0.080 |
Why?
| | Nonlinear Dynamics | 1 | 2010 | 88 | 0.080 |
Why?
| | Didanosine | 1 | 2010 | 13 | 0.080 |
Why?
| | Rural Population | 1 | 2014 | 560 | 0.080 |
Why?
| | Oxidation-Reduction | 1 | 2014 | 1059 | 0.080 |
Why?
| | Prevalence | 2 | 2015 | 2711 | 0.080 |
Why?
| | Phosphoglycerate Kinase | 1 | 2009 | 2 | 0.080 |
Why?
| | Activities of Daily Living | 2 | 2003 | 413 | 0.080 |
Why?
| | Antibody Formation | 2 | 2007 | 298 | 0.080 |
Why?
| | Sarcosine | 1 | 2009 | 10 | 0.080 |
Why?
| | Autoimmunity | 2 | 2025 | 908 | 0.080 |
Why?
| | CpG Islands | 2 | 2023 | 157 | 0.080 |
Why?
| | Decision Trees | 2 | 2020 | 93 | 0.080 |
Why?
| | Retinitis Pigmentosa | 1 | 2008 | 20 | 0.080 |
Why?
| | AIDS-Related Opportunistic Infections | 1 | 2010 | 127 | 0.080 |
Why?
| | Delivery of Health Care | 1 | 2016 | 934 | 0.080 |
Why?
| | Peptide Library | 2 | 2007 | 88 | 0.080 |
Why?
| | Genes, Recessive | 1 | 2008 | 78 | 0.070 |
Why?
| | Retrospective Studies | 6 | 2024 | 15504 | 0.070 |
Why?
| | Acculturation | 1 | 2008 | 53 | 0.070 |
Why?
| | Anti-HIV Agents | 1 | 2015 | 775 | 0.070 |
Why?
| | Psoriasis | 1 | 2009 | 102 | 0.070 |
Why?
| | Homozygote | 1 | 2008 | 203 | 0.070 |
Why?
| | Complex Mixtures | 1 | 2007 | 11 | 0.070 |
Why?
| | Antibodies, Viral | 2 | 2024 | 624 | 0.070 |
Why?
| | Receptors, Adrenergic, beta-2 | 1 | 2007 | 45 | 0.070 |
Why?
| | Blindness | 1 | 2008 | 38 | 0.070 |
Why?
| | Uncertainty | 1 | 2008 | 128 | 0.070 |
Why?
| | Models, Molecular | 2 | 2019 | 1570 | 0.070 |
Why?
| | Confidence Intervals | 1 | 2008 | 328 | 0.070 |
Why?
| | Xenopus | 1 | 2007 | 87 | 0.070 |
Why?
| | Glaucoma | 1 | 2010 | 234 | 0.070 |
Why?
| | Mice, Nude | 2 | 2021 | 696 | 0.070 |
Why?
| | Proteins | 2 | 2003 | 1008 | 0.070 |
Why?
| | Respiratory Tract Infections | 1 | 2011 | 394 | 0.070 |
Why?
| | Leisure Activities | 1 | 2007 | 32 | 0.070 |
Why?
| | Practice Patterns, Physicians' | 1 | 2016 | 1301 | 0.070 |
Why?
| | Antibodies, Neoplasm | 1 | 2007 | 34 | 0.070 |
Why?
| | Genes, myc | 1 | 2007 | 48 | 0.070 |
Why?
| | Decision Theory | 1 | 2006 | 1 | 0.070 |
Why?
| | Self Concept | 1 | 2009 | 249 | 0.070 |
Why?
| | Pituitary Neoplasms | 1 | 2009 | 190 | 0.070 |
Why?
| | Nails | 1 | 2007 | 12 | 0.070 |
Why?
| | Lymphatic Metastasis | 2 | 2019 | 351 | 0.070 |
Why?
| | Exercise | 1 | 2018 | 2043 | 0.070 |
Why?
| | Information Storage and Retrieval | 1 | 2007 | 117 | 0.070 |
Why?
| | Socioeconomic Factors | 2 | 2008 | 1282 | 0.070 |
Why?
| | Nepal | 2 | 2016 | 29 | 0.070 |
Why?
| | Genome, Bacterial | 2 | 2006 | 142 | 0.070 |
Why?
| | Genome, Human | 4 | 2016 | 423 | 0.060 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2023 | 3710 | 0.060 |
Why?
| | Genes, MHC Class II | 1 | 2006 | 74 | 0.060 |
Why?
| | Pharynx | 1 | 2006 | 59 | 0.060 |
Why?
| | Serine Endopeptidases | 1 | 2007 | 123 | 0.060 |
Why?
| | DNA, Bacterial | 2 | 2006 | 337 | 0.060 |
Why?
| | Haemophilus Infections | 1 | 2006 | 42 | 0.060 |
Why?
| | Arsenic | 1 | 2007 | 64 | 0.060 |
Why?
| | Structure-Activity Relationship | 1 | 2007 | 570 | 0.060 |
Why?
| | Haemophilus influenzae | 1 | 2006 | 63 | 0.060 |
Why?
| | Death Certificates | 1 | 2006 | 30 | 0.060 |
Why?
| | Cell Cycle Proteins | 2 | 2007 | 613 | 0.060 |
Why?
| | Biotinylation | 1 | 2005 | 32 | 0.060 |
Why?
| | GATA3 Transcription Factor | 1 | 2005 | 26 | 0.060 |
Why?
| | Calibration | 2 | 2022 | 146 | 0.060 |
Why?
| | Apoptosis | 3 | 2021 | 2551 | 0.060 |
Why?
| | Molecular Mimicry | 1 | 2005 | 42 | 0.060 |
Why?
| | Nephrocalcinosis | 1 | 2025 | 13 | 0.060 |
Why?
| | Diabetic Retinopathy | 1 | 2008 | 189 | 0.060 |
Why?
| | Antibodies, Anti-Idiotypic | 1 | 2005 | 59 | 0.060 |
Why?
| | Quantitative Trait Loci | 1 | 2008 | 380 | 0.060 |
Why?
| | United States | 7 | 2018 | 14691 | 0.060 |
Why?
| | Hydrogen Bonding | 1 | 2005 | 163 | 0.060 |
Why?
| | STAT5 Transcription Factor | 1 | 2025 | 57 | 0.060 |
Why?
| | Chromosomes, Human, Pair 17 | 1 | 2005 | 55 | 0.060 |
Why?
| | Family Characteristics | 2 | 2016 | 189 | 0.060 |
Why?
| | Disease-Free Survival | 3 | 2017 | 685 | 0.060 |
Why?
| | Sequence Homology, Amino Acid | 1 | 2005 | 385 | 0.060 |
Why?
| | Interleukin-15 | 1 | 2025 | 97 | 0.060 |
Why?
| | Carcinoma, Intraductal, Noninfiltrating | 1 | 2005 | 56 | 0.060 |
Why?
| | Protein Interaction Mapping | 1 | 2005 | 109 | 0.060 |
Why?
| | Histocompatibility Antigens Class II | 1 | 2006 | 368 | 0.060 |
Why?
| | Area Under Curve | 2 | 2020 | 314 | 0.060 |
Why?
| | Mobile Health Units | 1 | 2024 | 21 | 0.060 |
Why?
| | Environmental Pollutants | 1 | 2007 | 157 | 0.060 |
Why?
| | Lipids | 1 | 2009 | 665 | 0.060 |
Why?
| | Protein Structure, Secondary | 1 | 2005 | 374 | 0.060 |
Why?
| | Polymerase Chain Reaction | 3 | 2017 | 1059 | 0.060 |
Why?
| | Poisson Distribution | 1 | 2004 | 73 | 0.060 |
Why?
| | Retinal Rod Photoreceptor Cells | 1 | 2004 | 17 | 0.060 |
Why?
| | Linkage Disequilibrium | 1 | 2005 | 268 | 0.060 |
Why?
| | Granulomatous Disease, Chronic | 1 | 2004 | 55 | 0.060 |
Why?
| | Retinal Cone Photoreceptor Cells | 1 | 2004 | 19 | 0.060 |
Why?
| | Bed Occupancy | 1 | 2024 | 16 | 0.060 |
Why?
| | Culture Techniques | 1 | 2004 | 81 | 0.050 |
Why?
| | Sputum | 1 | 2006 | 311 | 0.050 |
Why?
| | Bacterial Typing Techniques | 1 | 2004 | 44 | 0.050 |
Why?
| | Environmental Monitoring | 1 | 2007 | 369 | 0.050 |
Why?
| | Fluorescent Antibody Technique | 2 | 2020 | 388 | 0.050 |
Why?
| | Gallium Radioisotopes | 1 | 2023 | 14 | 0.050 |
Why?
| | Cancer Vaccines | 1 | 2005 | 172 | 0.050 |
Why?
| | Otitis Media | 1 | 2006 | 165 | 0.050 |
Why?
| | Pedigree | 2 | 2019 | 514 | 0.050 |
Why?
| | Genetic Heterogeneity | 1 | 2004 | 59 | 0.050 |
Why?
| | Body Mass Index | 2 | 2016 | 2375 | 0.050 |
Why?
| | Polybrominated Biphenyls | 1 | 2003 | 2 | 0.050 |
Why?
| | Serotonin Plasma Membrane Transport Proteins | 1 | 2004 | 75 | 0.050 |
Why?
| | Genetics, Population | 1 | 2005 | 209 | 0.050 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 2009 | 858 | 0.050 |
Why?
| | Personality Inventory | 1 | 2004 | 139 | 0.050 |
Why?
| | Pandemics | 2 | 2023 | 1613 | 0.050 |
Why?
| | Cause of Death | 1 | 2006 | 430 | 0.050 |
Why?
| | Expressed Sequence Tags | 1 | 2003 | 42 | 0.050 |
Why?
| | Immunophenotyping | 2 | 2020 | 319 | 0.050 |
Why?
| | Signal-To-Noise Ratio | 1 | 2023 | 67 | 0.050 |
Why?
| | Wnt Proteins | 2 | 2020 | 133 | 0.050 |
Why?
| | GTPase-Activating Proteins | 1 | 2023 | 82 | 0.050 |
Why?
| | Immunity, Innate | 1 | 2009 | 825 | 0.050 |
Why?
| | Bile Ducts | 1 | 2003 | 71 | 0.050 |
Why?
| | Antibodies, Monoclonal | 2 | 2012 | 1430 | 0.050 |
Why?
| | Asthma | 2 | 2007 | 2282 | 0.050 |
Why?
| | Immunoglobulin M | 1 | 2024 | 289 | 0.050 |
Why?
| | Macrophages | 1 | 2011 | 1544 | 0.050 |
Why?
| | Biological Specimen Banks | 1 | 2024 | 102 | 0.050 |
Why?
| | Artifacts | 1 | 2023 | 129 | 0.050 |
Why?
| | Hyperplasia | 1 | 2003 | 175 | 0.050 |
Why?
| | T-Lymphocytes, Helper-Inducer | 1 | 2023 | 137 | 0.050 |
Why?
| | Antigens, Neoplasm | 1 | 2005 | 319 | 0.050 |
Why?
| | Breast | 1 | 2003 | 149 | 0.050 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 2 | 2021 | 851 | 0.050 |
Why?
| | Biguanides | 1 | 2022 | 12 | 0.050 |
Why?
| | Selection Bias | 1 | 2022 | 37 | 0.050 |
Why?
| | Receptors, Antigen, B-Cell | 1 | 2023 | 130 | 0.050 |
Why?
| | Hospitalization | 2 | 2024 | 2183 | 0.050 |
Why?
| | Bone Morphogenetic Proteins | 1 | 2023 | 135 | 0.050 |
Why?
| | Complement System Proteins | 1 | 2005 | 327 | 0.050 |
Why?
| | Lymphoma, B-Cell | 1 | 2003 | 106 | 0.050 |
Why?
| | T-Lymphocytes, Regulatory | 1 | 2025 | 387 | 0.050 |
Why?
| | Calcium Signaling | 1 | 2004 | 249 | 0.050 |
Why?
| | Motor Activity | 1 | 2007 | 717 | 0.050 |
Why?
| | Sarcoma, Ewing | 1 | 2003 | 96 | 0.050 |
Why?
| | Mice, Inbred C57BL | 2 | 2025 | 5749 | 0.050 |
Why?
| | Benchmarking | 1 | 2023 | 183 | 0.050 |
Why?
| | Membrane Proteins | 1 | 2008 | 1163 | 0.050 |
Why?
| | Genes, BRCA2 | 1 | 2002 | 29 | 0.050 |
Why?
| | Yeasts | 1 | 2002 | 53 | 0.050 |
Why?
| | Evaluation Studies as Topic | 1 | 2002 | 180 | 0.050 |
Why?
| | Genes, BRCA1 | 1 | 2002 | 38 | 0.050 |
Why?
| | Faculty, Medical | 1 | 2025 | 283 | 0.050 |
Why?
| | Vaccines, Synthetic | 1 | 2022 | 126 | 0.050 |
Why?
| | Seasons | 1 | 2024 | 544 | 0.050 |
Why?
| | Epithelial Cells | 2 | 2008 | 1094 | 0.050 |
Why?
| | Antigens, Protozoan | 1 | 2021 | 24 | 0.040 |
Why?
| | Entropy | 1 | 2021 | 40 | 0.040 |
Why?
| | Nucleic Acid Amplification Techniques | 1 | 2021 | 37 | 0.040 |
Why?
| | Japan | 1 | 2021 | 115 | 0.040 |
Why?
| | T-Lymphocyte Subsets | 1 | 2023 | 425 | 0.040 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2005 | 2052 | 0.040 |
Why?
| | Health Care Surveys | 2 | 2016 | 562 | 0.040 |
Why?
| | Citrullination | 1 | 2020 | 13 | 0.040 |
Why?
| | Evolution, Molecular | 1 | 2005 | 488 | 0.040 |
Why?
| | Genetic Testing | 1 | 2004 | 453 | 0.040 |
Why?
| | Leadership | 1 | 2025 | 382 | 0.040 |
Why?
| | Milk, Human | 1 | 2022 | 158 | 0.040 |
Why?
| | Somatostatin-Secreting Cells | 1 | 2020 | 3 | 0.040 |
Why?
| | Drosophila Proteins | 1 | 2002 | 205 | 0.040 |
Why?
| | Receptors, Retinoic Acid | 1 | 2020 | 43 | 0.040 |
Why?
| | Citalopram | 1 | 2020 | 29 | 0.040 |
Why?
| | Human Embryonic Stem Cells | 1 | 2020 | 24 | 0.040 |
Why?
| | Somatostatin | 1 | 2020 | 61 | 0.040 |
Why?
| | Immunoglobulin G | 1 | 2024 | 887 | 0.040 |
Why?
| | Immunity, Cellular | 1 | 2022 | 268 | 0.040 |
Why?
| | Leukocytes, Mononuclear | 1 | 2023 | 558 | 0.040 |
Why?
| | Policy | 1 | 2021 | 149 | 0.040 |
Why?
| | RNA, Ribosomal, 16S | 1 | 2022 | 549 | 0.040 |
Why?
| | Support Vector Machine | 1 | 2020 | 38 | 0.040 |
Why?
| | Polycomb Repressive Complex 2 | 3 | 2007 | 67 | 0.040 |
Why?
| | Nutrition Surveys | 1 | 2021 | 266 | 0.040 |
Why?
| | Embryo, Mammalian | 1 | 2020 | 232 | 0.040 |
Why?
| | Immunoblotting | 3 | 2005 | 306 | 0.040 |
Why?
| | Cognition Disorders | 1 | 2003 | 495 | 0.040 |
Why?
| | International Classification of Diseases | 1 | 2020 | 132 | 0.040 |
Why?
| | Allosteric Regulation | 1 | 2019 | 97 | 0.040 |
Why?
| | Nanog Homeobox Protein | 1 | 2019 | 13 | 0.040 |
Why?
| | Quality of Life | 2 | 2009 | 2878 | 0.040 |
Why?
| | Disease Vectors | 1 | 2019 | 16 | 0.040 |
Why?
| | Polymethyl Methacrylate | 1 | 2019 | 22 | 0.040 |
Why?
| | Skin | 2 | 2017 | 751 | 0.040 |
Why?
| | Electroencephalography | 1 | 2021 | 430 | 0.040 |
Why?
| | Leprosy | 1 | 2019 | 24 | 0.040 |
Why?
| | Disease Models, Animal | 2 | 2025 | 4282 | 0.040 |
Why?
| | Binding Sites | 2 | 2017 | 1301 | 0.040 |
Why?
| | Schizophrenic Psychology | 1 | 2019 | 94 | 0.040 |
Why?
| | Disease Susceptibility | 1 | 2020 | 345 | 0.040 |
Why?
| | Receptors, Antigen, T-Cell | 1 | 2023 | 718 | 0.040 |
Why?
| | Interferon-gamma | 1 | 2022 | 789 | 0.040 |
Why?
| | Breast Feeding | 1 | 2022 | 439 | 0.040 |
Why?
| | SEER Program | 1 | 2019 | 218 | 0.040 |
Why?
| | Herpesvirus 3, Human | 1 | 2022 | 332 | 0.040 |
Why?
| | Virulence | 2 | 2011 | 266 | 0.040 |
Why?
| | Basic Helix-Loop-Helix Transcription Factors | 1 | 2020 | 242 | 0.040 |
Why?
| | Malaria | 1 | 2019 | 63 | 0.040 |
Why?
| | Seizures | 1 | 2021 | 425 | 0.040 |
Why?
| | B-Lymphocytes | 1 | 2023 | 846 | 0.040 |
Why?
| | Epigenesis, Genetic | 2 | 2017 | 657 | 0.040 |
Why?
| | Mice, SCID | 1 | 2019 | 366 | 0.040 |
Why?
| | Prostatic Hyperplasia | 2 | 2008 | 42 | 0.040 |
Why?
| | Adjuvants, Immunologic | 1 | 2019 | 226 | 0.040 |
Why?
| | Autoantigens | 1 | 2020 | 428 | 0.040 |
Why?
| | Xenodiagnosis | 1 | 2017 | 2 | 0.030 |
Why?
| | Inflammation Mediators | 1 | 2020 | 513 | 0.030 |
Why?
| | Protein Domains | 1 | 2019 | 289 | 0.030 |
Why?
| | DNA, Protozoan | 1 | 2017 | 31 | 0.030 |
Why?
| | Kidney | 1 | 2025 | 1467 | 0.030 |
Why?
| | Protein Stability | 1 | 2018 | 176 | 0.030 |
Why?
| | Mice, Knockout | 2 | 2020 | 3008 | 0.030 |
Why?
| | National Cancer Institute (U.S.) | 1 | 2017 | 47 | 0.030 |
Why?
| | Taiwan | 2 | 2007 | 31 | 0.030 |
Why?
| | Mice, Inbred NOD | 1 | 2019 | 600 | 0.030 |
Why?
| | Databases, Protein | 2 | 2007 | 85 | 0.030 |
Why?
| | Michigan | 2 | 2007 | 108 | 0.030 |
Why?
| | Fibroblasts | 1 | 2002 | 993 | 0.030 |
Why?
| | Tissue Scaffolds | 1 | 2019 | 208 | 0.030 |
Why?
| | After-Hours Care | 1 | 2016 | 15 | 0.030 |
Why?
| | Enzyme Stability | 1 | 2016 | 70 | 0.030 |
Why?
| | Analgesia, Patient-Controlled | 1 | 2016 | 13 | 0.030 |
Why?
| | Sterilization, Tubal | 1 | 2016 | 16 | 0.030 |
Why?
| | Population Density | 1 | 2016 | 95 | 0.030 |
Why?
| | Platelet Count | 1 | 2016 | 85 | 0.030 |
Why?
| | Radiotherapy, Intensity-Modulated | 1 | 2017 | 142 | 0.030 |
Why?
| | Live Birth | 1 | 2016 | 65 | 0.030 |
Why?
| | Prostate-Specific Antigen | 2 | 2008 | 161 | 0.030 |
Why?
| | Prostate | 2 | 2008 | 175 | 0.030 |
Why?
| | Survivors | 1 | 2019 | 487 | 0.030 |
Why?
| | Enzyme Inhibitors | 1 | 2019 | 839 | 0.030 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2017 | 387 | 0.030 |
Why?
| | International Cooperation | 1 | 2016 | 198 | 0.030 |
Why?
| | Personnel Staffing and Scheduling | 1 | 2016 | 94 | 0.030 |
Why?
| | Enhancer of Zeste Homolog 2 Protein | 2 | 2007 | 51 | 0.030 |
Why?
| | Tuberculosis | 1 | 2019 | 279 | 0.030 |
Why?
| | Amino Acid Substitution | 1 | 2016 | 306 | 0.030 |
Why?
| | HEK293 Cells | 1 | 2018 | 729 | 0.030 |
Why?
| | Family | 1 | 2019 | 665 | 0.030 |
Why?
| | Cognition | 1 | 2003 | 1146 | 0.030 |
Why?
| | Cholesterol, HDL | 1 | 2016 | 203 | 0.030 |
Why?
| | Genes, Bacterial | 2 | 2006 | 164 | 0.030 |
Why?
| | Gene Regulatory Networks | 2 | 2007 | 304 | 0.030 |
Why?
| | Cell Movement | 1 | 2019 | 968 | 0.030 |
Why?
| | Cesarean Section | 1 | 2016 | 183 | 0.030 |
Why?
| | Rats | 1 | 2003 | 5639 | 0.030 |
Why?
| | Epistasis, Genetic | 1 | 2015 | 70 | 0.030 |
Why?
| | Neuropsychological Tests | 1 | 2019 | 1022 | 0.030 |
Why?
| | Particulate Matter | 1 | 2017 | 312 | 0.030 |
Why?
| | Cardiovascular System | 1 | 2016 | 137 | 0.030 |
Why?
| | Genes, Essential | 1 | 2014 | 23 | 0.030 |
Why?
| | Skin Neoplasms | 1 | 2002 | 852 | 0.030 |
Why?
| | Occupational Exposure | 1 | 2018 | 338 | 0.030 |
Why?
| | GATA1 Transcription Factor | 1 | 2014 | 18 | 0.030 |
Why?
| | Molecular Sequence Annotation | 1 | 2014 | 97 | 0.030 |
Why?
| | Data Collection | 2 | 2007 | 668 | 0.030 |
Why?
| | Hospitals, Public | 1 | 2013 | 29 | 0.030 |
Why?
| | Hospitals, Rural | 1 | 2013 | 39 | 0.030 |
Why?
| | Methylation | 1 | 2014 | 230 | 0.030 |
Why?
| | Receptors, Estrogen | 2 | 2007 | 436 | 0.030 |
Why?
| | Demography | 1 | 2014 | 291 | 0.030 |
Why?
| | North America | 1 | 2014 | 312 | 0.030 |
Why?
| | Organ Specificity | 1 | 2014 | 304 | 0.030 |
Why?
| | Host-Parasite Interactions | 1 | 2014 | 114 | 0.030 |
Why?
| | Gene-Environment Interaction | 1 | 2014 | 190 | 0.030 |
Why?
| | Species Specificity | 1 | 2014 | 586 | 0.030 |
Why?
| | Cell Line | 2 | 2009 | 2838 | 0.030 |
Why?
| | RNA Processing, Post-Transcriptional | 1 | 2013 | 92 | 0.030 |
Why?
| | Infusions, Intravenous | 1 | 2013 | 412 | 0.020 |
Why?
| | Sequence Analysis, DNA | 2 | 2006 | 809 | 0.020 |
Why?
| | Emergency Service, Hospital | 1 | 2024 | 2046 | 0.020 |
Why?
| | Cytokines | 1 | 2020 | 2084 | 0.020 |
Why?
| | Schizosaccharomyces | 1 | 2013 | 91 | 0.020 |
Why?
| | Carboplatin | 1 | 2012 | 142 | 0.020 |
Why?
| | Hydrogen | 1 | 2012 | 70 | 0.020 |
Why?
| | Cetuximab | 1 | 2012 | 95 | 0.020 |
Why?
| | Databases, Nucleic Acid | 1 | 2012 | 34 | 0.020 |
Why?
| | Methane | 1 | 2012 | 49 | 0.020 |
Why?
| | Drug Administration Schedule | 1 | 2013 | 785 | 0.020 |
Why?
| | Paclitaxel | 1 | 2012 | 227 | 0.020 |
Why?
| | In Situ Hybridization | 1 | 2011 | 316 | 0.020 |
Why?
| | Prospective Studies | 3 | 2009 | 7572 | 0.020 |
Why?
| | Quinazolines | 1 | 2012 | 250 | 0.020 |
Why?
| | Self Report | 1 | 2014 | 822 | 0.020 |
Why?
| | Depression | 1 | 2019 | 1395 | 0.020 |
Why?
| | Mass Screening | 1 | 2018 | 1267 | 0.020 |
Why?
| | Electrophoresis | 1 | 2009 | 32 | 0.020 |
Why?
| | Pituitary Hormones | 1 | 2009 | 16 | 0.020 |
Why?
| | Insulin | 1 | 2020 | 2406 | 0.020 |
Why?
| | Cell Death | 1 | 2011 | 372 | 0.020 |
Why?
| | Hospitals | 1 | 2014 | 685 | 0.020 |
Why?
| | Sarcosine Dehydrogenase | 1 | 2009 | 1 | 0.020 |
Why?
| | Glycine N-Methyltransferase | 1 | 2009 | 4 | 0.020 |
Why?
| | Bone Morphogenetic Protein Receptors, Type I | 1 | 2009 | 10 | 0.020 |
Why?
| | Ophthalmoscopy | 1 | 2008 | 36 | 0.020 |
Why?
| | Interleukin-1beta | 1 | 2011 | 371 | 0.020 |
Why?
| | Electroretinography | 1 | 2008 | 48 | 0.020 |
Why?
| | Consanguinity | 1 | 2008 | 49 | 0.020 |
Why?
| | Blood Pressure | 1 | 2016 | 1774 | 0.020 |
Why?
| | Gene Library | 1 | 2009 | 116 | 0.020 |
Why?
| | Mice, Mutant Strains | 1 | 2009 | 298 | 0.020 |
Why?
| | Gene Expression Regulation, Bacterial | 1 | 2011 | 324 | 0.020 |
Why?
| | Antineoplastic Agents | 2 | 2012 | 2122 | 0.020 |
Why?
| | Golgi Apparatus | 1 | 2008 | 100 | 0.020 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2017 | 1682 | 0.020 |
Why?
| | Chemical Fractionation | 1 | 2007 | 26 | 0.020 |
Why?
| | Genes | 1 | 2008 | 230 | 0.020 |
Why?
| | Gene Knockdown Techniques | 1 | 2009 | 327 | 0.020 |
Why?
| | Chromosomes, Human, 16-18 | 1 | 2007 | 3 | 0.020 |
Why?
| | Chromosomes, Human, 6-12 and X | 1 | 2007 | 3 | 0.020 |
Why?
| | Keratinocytes | 1 | 2009 | 248 | 0.020 |
Why?
| | Polycomb-Group Proteins | 1 | 2007 | 28 | 0.020 |
Why?
| | DNA Primers | 1 | 2008 | 514 | 0.020 |
Why?
| | Chromosomes, Human, Pair 5 | 1 | 2007 | 30 | 0.020 |
Why?
| | Chromosomes, Human, Pair 3 | 1 | 2007 | 50 | 0.020 |
Why?
| | Feedback | 1 | 2008 | 173 | 0.020 |
Why?
| | Bacteriophage T7 | 1 | 2007 | 5 | 0.020 |
Why?
| | Seaweed | 1 | 2007 | 2 | 0.020 |
Why?
| | Oxygen | 1 | 2012 | 930 | 0.020 |
Why?
| | Chromatography, Liquid | 1 | 2009 | 433 | 0.020 |
Why?
| | Agaricales | 1 | 2007 | 4 | 0.020 |
Why?
| | Neoplasm Transplantation | 1 | 2007 | 257 | 0.020 |
Why?
| | Models, Animal | 1 | 2009 | 384 | 0.020 |
Why?
| | Subtraction Technique | 1 | 2007 | 23 | 0.020 |
Why?
| | Data Display | 1 | 2007 | 21 | 0.020 |
Why?
| | Autophagy-Related Proteins | 1 | 2007 | 46 | 0.020 |
Why?
| | Chromosomes, Human | 1 | 2007 | 44 | 0.020 |
Why?
| | Seafood | 1 | 2007 | 27 | 0.020 |
Why?
| | Tomography, Optical Coherence | 1 | 2008 | 213 | 0.020 |
Why?
| | Food Contamination | 1 | 2007 | 48 | 0.020 |
Why?
| | Oxidative Stress | 1 | 2013 | 1314 | 0.020 |
Why?
| | Sequence Analysis, Protein | 1 | 2006 | 30 | 0.020 |
Why?
| | Oryza | 1 | 2007 | 33 | 0.020 |
Why?
| | Lymphoma | 1 | 2008 | 208 | 0.020 |
Why?
| | Television | 1 | 2007 | 75 | 0.020 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2012 | 801 | 0.020 |
Why?
| | Inhibitory Concentration 50 | 1 | 2006 | 90 | 0.020 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2013 | 1095 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 2019 | 5742 | 0.020 |
Why?
| | Managed Care Programs | 1 | 2007 | 130 | 0.020 |
Why?
| | Fishes | 1 | 2007 | 103 | 0.020 |
Why?
| | Water Supply | 1 | 2007 | 78 | 0.020 |
Why?
| | Nucleic Acid Hybridization | 1 | 2006 | 190 | 0.020 |
Why?
| | Ear, Middle | 1 | 2006 | 85 | 0.020 |
Why?
| | Urban Health | 1 | 2006 | 92 | 0.020 |
Why?
| | Drug Design | 1 | 2007 | 167 | 0.020 |
Why?
| | Lipid Metabolism | 1 | 2009 | 512 | 0.020 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2011 | 1242 | 0.020 |
Why?
| | Recombinant Proteins | 1 | 2009 | 1350 | 0.020 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2014 | 1320 | 0.020 |
Why?
| | Fibrocystic Breast Disease | 1 | 2005 | 2 | 0.020 |
Why?
| | Databases as Topic | 1 | 2005 | 67 | 0.010 |
Why?
| | E2F Transcription Factors | 1 | 2005 | 60 | 0.010 |
Why?
| | Base Composition | 1 | 2005 | 78 | 0.010 |
Why?
| | Oligonucleotide Probes | 1 | 2005 | 51 | 0.010 |
Why?
| | DNA Probes | 1 | 2005 | 60 | 0.010 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2007 | 366 | 0.010 |
Why?
| | Neoplasms, Hormone-Dependent | 1 | 2004 | 38 | 0.010 |
Why?
| | Bone Morphogenetic Protein Receptors | 1 | 2004 | 6 | 0.010 |
Why?
| | Autopsy | 1 | 2004 | 93 | 0.010 |
Why?
| | Smad Proteins | 1 | 2004 | 42 | 0.010 |
Why?
| | Receptors, Growth Factor | 1 | 2004 | 55 | 0.010 |
Why?
| | Basic-Leucine Zipper Transcription Factors | 1 | 2004 | 41 | 0.010 |
Why?
| | Random Allocation | 1 | 2005 | 353 | 0.010 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2007 | 428 | 0.010 |
Why?
| | Recombination, Genetic | 1 | 2005 | 200 | 0.010 |
Why?
| | Oligonucleotides | 1 | 2004 | 148 | 0.010 |
Why?
| | Receptors, Progesterone | 1 | 2005 | 349 | 0.010 |
Why?
| | Retinal Diseases | 1 | 2004 | 91 | 0.010 |
Why?
| | Selection, Genetic | 1 | 2005 | 264 | 0.010 |
Why?
| | Spermine | 1 | 2002 | 27 | 0.010 |
Why?
| | Overweight | 1 | 2007 | 557 | 0.010 |
Why?
| | Spermidine | 1 | 2002 | 19 | 0.010 |
Why?
| | Genes, Tumor Suppressor | 1 | 2002 | 86 | 0.010 |
Why?
| | Internet | 1 | 2007 | 647 | 0.010 |
Why?
| | Adenosine Monophosphate | 1 | 2002 | 66 | 0.010 |
Why?
| | California | 1 | 2003 | 428 | 0.010 |
Why?
| | Mental Recall | 1 | 2003 | 201 | 0.010 |
Why?
| | Cell Cycle | 1 | 2004 | 601 | 0.010 |
Why?
| | Biopsy, Needle | 1 | 2002 | 189 | 0.010 |
Why?
| | Psychiatric Status Rating Scales | 1 | 2003 | 547 | 0.010 |
Why?
| | Comorbidity | 1 | 2006 | 1614 | 0.010 |
Why?
| | Proto-Oncogene Proteins | 1 | 2004 | 647 | 0.010 |
Why?
| | Bacterial Proteins | 1 | 2006 | 873 | 0.010 |
Why?
| | Transfection | 1 | 2002 | 941 | 0.010 |
Why?
| | RNA | 1 | 2005 | 921 | 0.010 |
Why?
| | Predictive Value of Tests | 1 | 2002 | 2022 | 0.010 |
Why?
| | Stroke | 1 | 2003 | 1118 | 0.010 |
Why?
| | Aging | 1 | 2003 | 1864 | 0.010 |
Why?
|
|
Ghosh's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|